Natera (NTRA) Stock: Earnings, Revenue and Analyst Targets
A full breakdown of NTRA's financials, analyst estimates, and key metrics every trader needs to know before taking a position.
Natera, Inc. (NASDAQ: NTRA) is one of the more closely watched names in the genetic testing space, and for good reason — the stock combines genuine revenue growth with the kind of volatility that can make or break a swing trade. If you're sizing up a position, you need to know where earnings, revenue, and analyst forecasts actually stand.
On the fundamentals side, NTRA's financials cover the full picture: historical earnings performance, forward estimates, and how the company's revenue trajectory is shaping up against Wall Street expectations. Market cap and volatility metrics round out the snapshot, giving you a clearer sense of the risk you're taking on with every share.
Read more OpenAI IPO Odds: Traders Bet on 2027 Over 2026 →
Analyst forecasts are a key input here. Consensus estimates on both the top and bottom lines tell you whether the Street thinks Natera is growing into its valuation — or whether it still has something to prove. Earnings beats and misses relative to those forecasts are what move this stock, so knowing the baseline matters before any catalyst hits.
Volatility is part of the NTRA story. The stock has historically moved sharply around earnings events, meaning options traders and momentum players both have a reason to watch the calendar closely. Understanding the historical performance data helps you frame what a "normal" move looks like versus a genuine surprise.
Whether you're a long-term investor building a biotech position or a short-term trader looking for a setup, the actuals-versus-estimates framework is your starting point. Continue reading at TradingView.
